DPC2019 is kindly supported by:
Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk.
GlucoRx is a leading supplier of quality, cost-effective diabetes management solutions: Innovative Nexus and HCT glucometers; FinePoint – UK’s most prescribed Insulin pen needle; Safety Lancets; Allpresan® – UK’s first clinically-approved diabetic foot moisturiser; Automatic HbA1c Analyser with embedded printer.
GlucoRx provides free diabetic reviews, bespoke training and EQA.
Takeda UK Ltd is a wholly owned subsidiary of Japan’s largest pharmaceutical company – a global industry leader with more than 30,000 employees in 70 countries and a heritage of more than 230 years. Our mission is to strive towards better health for people worldwide through leading innovation in medicine.
With over 100 years’ experience in healthcare solutions and services, BD remains focused on helping to achieve improved patient health outcomes by providing education and services, both for Health Care Professionals and patients(1,2). BD is the sponsor of multinational clinical trials, which identify the benefits of injection technique(2,3). BD works with hospitals, Diabetes centres, Primary care and community pharmacy with different solutions, to help achieve better outcomes for patients with Diabetes and also to protect staff and Healthcare organisations. Partner with BD to see the difference of Evidence.
(1) Smith M., Clapham L. & Strauss K. UK lipohypertrophy interventional study. Diabetes Research and Clinical Practice. 126 (2017) 248-253
(2) Grassi G., et al. Optimizing injection technique and its effect on blood glucose control. Journal of Clinical & Transformational Endocrinology 1 (2014) 145-150 (this is an open access article)
(3) Campinos, C, MD, Le Floch, L-P, MD, Petit, C, MD et al. Diabetes Technology & Therapeutics. Volume 19, Number 11, 2017.
Diabetes Research & Wellness Foundation
DRWF is registered charity (no. 1070607) established in 1998 to raise awareness to Type 1 and Type 2 diabetes; to provide information and support to people living with the conditions and to fund research to establish causes, treatment, management and ultimately, to find a cure.
Supported self-management is key to achieving the best possible results. Life with diabetes presents many challenges which require collective solution finding and we provide opportunities for those living with, and working in the field of diabetes and related health, to come together within a like-minded community to tackle those challenges together.
We are delighted to support DPC2018 as an initiative that reflects our own thinking.
The following Pharmaceutical Companies have provided financial support for venue hire, exhibition space and catering. They have had no influence over the content, or organisation of the meeting:
Boehringer Ingelheim & Lilly Alliance